If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
214
results.
Updated on
16/02/2026 [06:51:00]
Results 75 to 100 of 214
Absstract of: CN121013733A
Described herein are lipid nanoparticle (LNP) formulations for the delivery of active agents, including Archexin.
Absstract of: EP4691619A1
The present invention relates to a device useful for producing nanoparticles that include hydrophobic and hydrophilic substances. Specifically, the device according to the present invention is characterized by including: a plurality of inlet channels into which the hydrophobic and hydrophilic substances are respectively introduced; a mixing channel in which the substances are mixed to produce the nanoparticles; and an outlet channel through which the produced nanoparticles are discharged, wherein the mixing channel includes microposts capable of increasing the mixing efficiency of the substances. Therefore, the nanoparticles produced using the device according to the present invention exhibit excellent particle uniformity and can be effectively used as drugs or drug delivery carriers.
Absstract of: AU2024250317A1
The present disclosure relates to an RNA delivery vehicle comprising lipid nanoparticles comprising the RNA therein, and a RNA-binding protein or peptide coated on the exterior surface of the lipid nanoparticle, and uses thereof.
Absstract of: EP4691476A1
The present invention provides a method for producing nucleic acid-encapsulating lipid nanoparticles, including the following steps (a) and (b):step (a) of mixing an alcohol solution containing an ionic lipid having a tertiary amino group, a sterol, and a PEG lipid with a citrate buffer having pH 3 to 6.5 in which nucleic acid is dispersed to prepare a suspension of nucleic acid-encapsulating lipid nanoparticles; andstep (b) of exchanging a dispersion medium of the aforementioned suspension for a Tris buffer having pH 5.2 to 9.0 by concentrating the suspension of nucleic acid-encapsulating lipid nanoparticles by ultrafiltration and diluting same with the aforementioned Tris buffer.
Absstract of: CN121001708A
The invention relates to an oil-in-water nanoemulsion in a stable pressurized container. The nanovesicles contained in the nanoemulsion are particularly stable in terms of vesicle particle size and vesicle particle size uniformity after long-term storage at different temperatures.
Absstract of: CN120826370A
The invention relates to a method for synthesizing nanoparticles consisting of or comprising at least one zeolite nanocrystal, comprising:-preparing a first composition/solution 1 comprising a source of aluminum and a source of ions of an alkali metal M, in particular of Na; preparing a second composition/solution 2 containing a source of silicon and a source of ions of an alkali metal M, in particular of Na, said compositions/solutions 1 and 2 being free of any organic structure directing agent; -mixing compositions/solutions 1 and 2 and placing the mixture under stirring; crystallizing the mixture at a temperature greater than or equal to 50 DEG C; and-optionally separating the formed nanoparticles. According to the invention, the first composition/solution 1 and the second composition/solution 2 each consist of said source and an alkaline phosphate buffer (PBS). The invention also relates to the nanoparticles thus obtained and to compositions containing these nanoparticles.
Absstract of: EP4691478A1
The present invention relates to a pharmaceutical composition for treating cartilage damage disease, the pharmaceutical composition comprising magnetic nanoparticle-internalized nasal septum chondrocytes as an active ingredient. In addition, the present invention established a method of incorporating magnetic nanoparticles into nasal septum chondrocytes and a method of producing spheroids by culturing the magnetic nanoparticle-internalized nasal septum chondrocytes. The magnetic nanoparticle-internalized nasal septum chondrocytes manufactured by the methods of the present invention, and spheroids produced therefrom were confirmed to exhibit cartilage damage treatment activity while maintaining mobility in a magnetic field. In addition, since the activity is maintained even when the magnetic nanoparticle-internalizednasal septum chondrocytes and nasal septum chondrocytes are mixed to produce spheroids, the addition ratio of the magnetic nanoparticles can be significantly reduced, so that it can be usefully utilized as a composition for treating cartilage damage disease with excellent therapeutic effects without causing side effects.
Absstract of: CN121489871A
本发明属于药物制剂领域，提供了一种用于难溶性药物肺部给药的辅料体系及其制备方法。本发明采用脂质包覆难溶性药物纳米晶核壳颗粒与三元脂质分散中间体协同设计，通过抗溶剂沉淀原位包覆与高压微射流细化技术，将尼达尼布纳米晶外表面包覆由二棕榈酰‑sn‑甘油‑3‑磷酰胆碱、胆固醇和丙二醇辛酸酯构成的脂质壳层，形成质量中值粒径D50值为150‑250nm、体积分布D90值为≤400nm的核壳颗粒。本发明实现了高载药量、低黏度可雾化、优选肺部沉积分布和长期粒径稳定性，有效缓解了难溶性药物肺部给药中高固含与流变性能、低刺激性与胶体稳定性、雾化效率与核壳结构完整性之间的矛盾，具有广泛的临床应用价值。
Absstract of: CN121490077A
本发明的目的在于提供一种“光热联合化疗”治疗肿瘤的有机物‑有机物纳米复合物的制备方法及应用，属于抗肿瘤药物技术领域，本发明采用溶剂交换法制备了尺寸均一的1,4‑苯二异硫氰酸酯‑吲哚菁绿纳米复合物。得到的PDITC@ICG纳米复合物可以在近红外激光的激发下由光能转换为热能致局部升温导致癌细胞凋亡，并且与化疗之间起到相互增效的作用，实现了协同治疗肿瘤的效果。该种治疗方法具有明显的抑制肿瘤生长甚至达到肿瘤完全消失的效果。该体系具有良好的生物相容性和生物安全性，可以为临床三阴性乳腺癌患者提供一种具有时空精确性且诊疗一体化的潜在治疗方案。
Absstract of: CN121494840A
本发明属于抗菌材料技术领域，特别涉及一种两性离子型的光敏剂材料、纳米粒子及其制备方法和应用。本发明两性离子型的光敏剂材料的结构式为：；其中，x取3‑5之间的任意整数；R1、R2基团均为：。本发明基于磺酸化的两性离子型光敏剂材料具有优异亲水性和生物活性，可在低剂量下完成高效杀菌作用，对小鼠活体伤口感染具有高效的治愈性，因此可用于制备治疗伤口感染的药物，解决现有技术中聚集导致荧光猝灭效应，以及聚集导致ROS产率下降所导致的抗菌治疗效果不佳的问题。
Absstract of: CN121489901A
本发明属于药物制剂新剂型与靶向递送技术领域，涉及一种基于代谢酶相关的淫羊藿素前药或其药学上可接受的盐的纳米粒与菊粉凝胶的复合制剂及其制备方法与应用。本发明将淫羊藿素氨基甲酸酯前药或其药学上可接受的盐制备成PLGA纳米粒以提高其溶解度，并将该纳米粒嵌入菊粉凝胶中，构建了一种口服结肠靶向递药系统。为解决难溶性药物递送及炎症性肠病及其并发症的高效治疗提供了新的策略与选择。
Absstract of: CN121495105A
本发明公开了一种二硒键链接硝基咪唑与聚乙二醇的两亲性分子及其应用，属于医药技术领域。本发明提供一种通过二硒键链接硝基咪唑与聚乙二醇的两亲性分子MNZ‑Se2‑PEG，结构式如(Ⅰ)所示。该两亲性分子通过自组装可以包载化疗药物形成递药系统。制备的递药系统具有生理条件下可保持结构稳定、可通过辐射响应性释放药物和放疗增敏等优势，起到放化疗协同治疗作用；而且制备的递药系统生物安全性好。本发明为实现放化疗的协同增效提供了一个可靠的载体平台，具备优异的化疗药物递送系统开发潜力。
Absstract of: CN121489903A
本发明属于生物医药技术领域，具体涉及M2巨噬细胞膜包裹的ROS响应型仿生纳米递送系统及其制备方法和应用。M2巨噬细胞膜包裹的ROS响应型仿生纳米递送系统由搭载治疗药物的ROS响应纳米颗粒和包裹在所述ROS响应纳米颗粒外的M2巨噬细胞膜组成。本发明所提供的M2巨噬细胞膜包裹的ROS响应型仿生纳米递送系统生物相容性优异，具有免疫逃逸、精准靶向、清除细胞内ROS、抑制炎症损伤和细胞凋亡等功能，为动脉粥样硬化提供了一种兼具靶向递送、智能释药及多维度调控的仿生纳米递送系统。
Absstract of: CN121490096A
本发明公开了一种超小丹酚酸B‑铕金属多酚网络，其由丹酚酸B、EuCl3·6H2O和牛血清白蛋白自组装而成。本发明还公开了所述超小丹酚酸B‑铕金属多酚网络的制备方法及其在制备用于治疗肾结石的药物中的应用。本发明的超小丹酚酸B‑铕金属多酚网络SAB‑Eu@BSA兼具结晶抑制、调节氧化应激稳态和肾可清除特性，在草酸钙肾病治疗方面显示出巨大的潜力。
Absstract of: CN121489900A
本申请涉及一种靶向恶性肿瘤的藤黄酸制剂的制备与应用。采用内核‑中层‑外壳三层结构：内核为藤黄酸‑黑磷量子点复合物，兼具化学治疗与光热治疗功能；中层为冷冻化NK92 MI细胞来源的纳米囊泡，提供天然免疫靶向与杀伤能力；外壳为透明质酸螯合物，实现主动靶向与pH/光热响应型药物控制释放。其制备方法核心在于采用同轴电喷射技术，将三层物料一步成型，工艺高效且制剂稳定性好。该制剂能够实现光热‑化学‑免疫三重协同治疗，并同时具备近红外荧光与光声多模成像功能，有效解决了传统化疗靶向性差、毒副作用大及缺乏实时监控的难题，在实体瘤的精准治疗与诊断中展现出显著优势和应用潜力。
Absstract of: CN121490050A
本发明公开了一种基于传统中药复方的抗宫颈癌纳米靶向片剂及其制备方法，所述纳米靶向片剂由以下重量份的原料组成：蜈蚣、金钱白花蛇、海龙、全蝎、露蜂房、水蛭、土鳖虫、乳香、没药、蒲公英、香附、柴胡、枳壳、黄柏、当归、郁金、茯苓、白术、白芍、合欢皮、山药、白花蛇舌草和夏枯草。本发明将中药材通过现代提取技术最大化保留并富集活性成分，确保最大限度保留原方疗效，而通过叶酸受体、CD44受体及pH敏感三重靶向机制，使药物富集于宫颈癌组织，提高局部药物浓度，降低系统毒性，实现精准靶向递送。
Absstract of: MX2025013363A
The present disclosure describes compounds of Formula (I) and pharmaceutically acceptable salts thereof:
Absstract of: MX2025013817A
The present disclosure relates to a process for the preparation of tolerizing immune modifying nanoparticles encapsulating antigens associated with primary biliary cholangitis (PBC), compositions comprising the particles and use thereof for the treatment of PBC.
Absstract of: AU2025279611A1
The invention relates to double-stranded ribonucleic acid (dsRNA) targeting an APOC3 gene, and methods of using the dsRNA to inhibit expression of APOC3. ec e c
Absstract of: CN120659628A
The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from the group consisting of PEG-E1-A-E2-U-H and H-U-E1-A-E2-PEG wherein E1 is the N-terminal extension, E2 is the C-terminal extension, A is a peptide antigen, H is a hydrophobic block wherein one or more drug molecules (D) are optionally attached to each H either directly or via a suitable linker X1; u is a linker, represents a group being optional, and-represents that two adjacent groups are attached to each other directly via a covalent bond or indirectly via a suitable linker X. The vaccine can be used to treat or prevent cancer, autoimmune disease, allergy or infectious disease.
Absstract of: US2025339506A1
This invention relates to compositions (e.g., vaccine compositions) which can be used to immunise against Chlamydia infections. The compositions comprise Chlamydia sp. antigens and antigen combinations which can be used to immunise against Chlamydia sp., used in the form of nucleic acids (e.g., mRNAs) encoding antigenic proteins or in the form of recombinant protein antigens.
Absstract of: CN120813699A
Provided herein are a method of preparing a circular RNA, a method of isolating a circular RNA, and a composition comprising a circular RNA.
Absstract of: CN120548194A
The present disclosure relates to hMPV F, PIV3F, and PIV1F protein mutants, nucleic acids or vectors encoding the hMPV F, PIV3F, and PIV1F protein mutants, compositions comprising the hMPV F, PIV3F, and PIV1F protein mutants or nucleic acids, and uses of the hMPV F, PIV3F, and PIV1F protein mutants, nucleic acids or vectors, and compositions.
Absstract of: AU2024209240A1
The invention relates to a composition comprising or essentially consisting of (i) nanoparticles comprising or essentially consisting of Enzalutamide in crystalline form and (ii) one or more physiologically acceptable polymers and/or copolymers. The invention also relates to processes for the preparation of such compositions, pharmaceutical dosage forms comprising or made from such compositions, and uses of such pharmaceutical dosage forms for medical purposes.
Nº publicación: CN121495950A 10/02/2026
Applicant:
南阳师范学院
Absstract of: CN121495950A
本发明属于生物医药技术领域，提供一种猪急性腹泻综合征冠状病毒的S蛋白祖先序列AS mRNA，通过系统发育分析，构建SADS‑CoV Spike蛋白的祖先序列，该序列不仅针对现有的病毒，还针对病毒的进化谱系；利用该序列设计的从针对单一病原体的目标性防御转变为对病毒进化轨迹的主动干预；制备的AS mRNA疫苗对动物的饲养安全和人畜共患疾病的防控具有重要意义。
BOPI
Electronic site
